Indo Us Biotech working capital

·FMCG & RetailChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
387.96×387.96×355.10×
47.52×47.52×52.73×
3.66×3.66×5.84×
431.82×431.82×401.99×
1.11×1.36×1.48×
0.96×0.96×1.06×
−1.23×−1.23×−0.09×
−0.95×−0.95×−0.07×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

INDOUS₹78.36

Indo Us Biotech Limited

· FMCG & Retail
₹ CrorePeersKOHINOORNATHBIOGENAGRITECHSARVESHWARSUKHJITSREGAALBSHSLGULPOLYMcap ₹157 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Inventory Days (DIO)355.10387.96387.96
Receivable Days (DSO)52.7347.5247.52
Payable Days (DPO)5.843.663.66
Cash Conversion Cycle (days)401.99431.82431.82
Working Capital Turnover1.481.361.11
Asset Turnover1.060.960.96
Cash Conversion (CFO/Net Income)-0.09-1.23-1.23
CFO/EBITDA-0.07-0.95-0.95
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.